Sei Investments Co. Buys New Stake in Tenaya Therapeutics, Inc. (NASDAQ:TNYA)

Sei Investments Co. purchased a new position in shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA) in the fourth quarter, HoldingsChannel reports. The institutional investor purchased 69,702 shares of the company’s stock, valued at approximately $100,000.

Other institutional investors also recently added to or reduced their stakes in the company. SG Americas Securities LLC raised its holdings in shares of Tenaya Therapeutics by 61.9% in the 4th quarter. SG Americas Securities LLC now owns 41,270 shares of the company’s stock worth $59,000 after buying an additional 15,777 shares in the last quarter. State Street Corp grew its position in Tenaya Therapeutics by 0.9% in the third quarter. State Street Corp now owns 1,058,898 shares of the company’s stock valued at $2,044,000 after acquiring an additional 9,506 shares during the period. Spire Wealth Management bought a new stake in Tenaya Therapeutics in the fourth quarter valued at $53,000. Geode Capital Management LLC raised its stake in Tenaya Therapeutics by 5.4% during the third quarter. Geode Capital Management LLC now owns 1,296,156 shares of the company’s stock worth $2,502,000 after acquiring an additional 66,968 shares in the last quarter. Finally, XTX Topco Ltd lifted its holdings in shares of Tenaya Therapeutics by 51.2% during the third quarter. XTX Topco Ltd now owns 49,290 shares of the company’s stock valued at $95,000 after acquiring an additional 16,687 shares during the period. 90.54% of the stock is owned by institutional investors and hedge funds.

Tenaya Therapeutics Trading Up 12.0 %

TNYA opened at $0.49 on Friday. Tenaya Therapeutics, Inc. has a 1-year low of $0.39 and a 1-year high of $4.96. The stock has a market capitalization of $43.17 million, a PE ratio of -0.34 and a beta of 2.98. The firm has a 50-day moving average price of $0.74 and a two-hundred day moving average price of $1.56.

Tenaya Therapeutics (NASDAQ:TNYA) last posted its quarterly earnings data on Monday, March 17th. The company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.04. On average, research analysts predict that Tenaya Therapeutics, Inc. will post -1.35 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on TNYA shares. Morgan Stanley lowered their target price on shares of Tenaya Therapeutics from $15.00 to $5.00 and set an “overweight” rating on the stock in a report on Wednesday, March 12th. Chardan Capital decreased their price objective on shares of Tenaya Therapeutics from $18.00 to $9.00 and set a “buy” rating on the stock in a research note on Wednesday, March 12th. Canaccord Genuity Group cut their target price on shares of Tenaya Therapeutics from $18.00 to $6.00 and set a “buy” rating for the company in a research note on Thursday, March 13th. Finally, HC Wainwright restated a “buy” rating and set a $5.00 price target on shares of Tenaya Therapeutics in a research report on Monday, March 31st. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $6.25.

Insider Transactions at Tenaya Therapeutics

In other Tenaya Therapeutics news, major shareholder Group Gp Lp Column III bought 35,714,284 shares of Tenaya Therapeutics stock in a transaction dated Wednesday, March 5th. The shares were bought at an average price of $0.70 per share, with a total value of $24,999,998.80. Following the purchase, the insider now owns 49,313,559 shares of the company’s stock, valued at $34,519,491.30. This trade represents a 262.62 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders sold a total of 19,621 shares of company stock worth $10,595 over the last 90 days. 32.76% of the stock is owned by insiders.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.